Payment overview · 2025
General Payments
$172,879.79
237 reported records · 11 companies
Healthcare provider profile · identity verified
David N Pham, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · WESTMINSTER, CA · NPI 1043401698
Verified facts
What the public records show
CMS Open Payments records show David N Pham, MD received $172,879.79 in general payments during 2025 across 237 reported records.
AstraZeneca Pharmaceuticals LP accounted for 87.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Fasenra, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Zenpep by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FASENRA as an associated drug or biological on 40035 records involving 10417 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fasenra by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151,937.90 | 87.9% | 159 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20,048.11 | 11.6% | 51 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $443.60 | 0.3% | 13 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $101.61 | 0.1% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $83.30 | 0.1% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $71.73 | 0.0% | 3 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.65 | 0.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.89 | 0.0% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $32.01 | 0.0% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $28.94 | 0.0% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $15.05 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150,750.00 | 56 |
| Travel and Lodging | $15,904.42 | 53 |
| Food and Beverage | $6,208.16 | 126 |
| Gift | $17.21 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $111,813.74 | 108 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39,922.35 | 45 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $18,950.73 | 38 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $518.79 | 14 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $151.85 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $101.61 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $83.30 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $71.73 | 3 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.89 | 2 | 2025 |
Source payment records
|
|||||
| AIRSEAL Normalized: airseal |
Device | CONMED Corporation | $28.94 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $24.68 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FASENRA fasenra |
2025 | Fasenra | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FASENRA open payments reported associated product |
CMS Open Payments — General Payments 40035 supporting records · 10417 recipient NPIs · example record 1206131346 |
Fasenra · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 646 | 153 |
| Montelukast Sodium | Montelukast Sodium | 255 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 252 | 77 |
| Ventolin Hfa | Albuterol Sulfate | 207 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 149 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 129 | 48 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 122 | 38 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 113 | 25 |
| Famotidine | Famotidine | 108 | 34 |
| Dupixent Syringe | Dupilumab | 95 | 18 |
| Gabapentin | Gabapentin | 93 | 20 |
| Meloxicam | Meloxicam | 87 | 28 |
| Metformin Hcl | Metformin Hcl | 71 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 18 |
| Restasis | Cyclosporine | 58 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 54 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 54 | 16 |
| Azithromycin | Azithromycin | 51 | 25 |
| Celecoxib | Celecoxib | 51 | 16 |
| Hydrocortisone | Hydrocortisone | 51 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 51 | 16 |
| Meclizine Hcl | Meclizine Hcl | 49 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 46 | 13 |
| Losartan Potassium | Losartan Potassium | 38 | 11 |
| Furosemide | Furosemide | 37 | suppressed |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Prednisone | Prednisone | 33 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 29 | suppressed |
| Allopurinol | Allopurinol | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | 12 |
| Dupixent Pen | Dupilumab | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Telmisartan | Telmisartan | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Omeprazole | Omeprazole | 22 | suppressed |
| Xolair | Omalizumab | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 19 | suppressed |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | suppressed |
| Fasenra | Benralizumab | 17 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Tracleer | Bosentan | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Lisinopril | Lisinopril | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Adempas | Riociguat | 12 | suppressed |
| Airsupra | Albuterol Sulfate/Budesonide | 12 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 12 | suppressed |
| Uptravi | Selexipag | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $172,879.79 · 237 records | AstraZeneca Pharmaceuticals LP | AIRSEAL, AIRSUPRA, Arikayce, BREZTRI, Brinsupri, DUPIXENT, FASENRA, JASCAYD, NUCALA, Ohtuvayre, SMARTVEST, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error